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broadcast antismoking commercials, smoking restrictions in
restaurants and private workplaces, the radio and television
ad ban, and the tar/nicotine listing requirement.3 The 1971
radio and television ad ban resulted in about a 27.8% savings
in real ad spending for cigarette companieswith no detectable
reduction in demand.3 To be prudent, a total ad ban should be
accompanied by controls on the introduction ofnew cigarette
brands/varieties and by antismoking policies known to reduce
consumption.
Such effective measures include excise tax increases, res¬
taurant smoking restrictions, and broadcasting antismoking
commercials. For each 10% increase in real cigarette price, a
demand decrease of approximately 3.7% results.3 For each
10% increase in the smoking-age population covered by gov¬
ernment smoking restrictions, a drop in demand of around
6.5% is seen.3 An optimal antismoking agenda would give
highest priority to these efficacious policies.
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In Reply.\p=m-\Smokingis a highly complex and insufficiently
understood behavior. Consequently, effective reductions in
smoking behavior are likely to be achieved through a com-
prehensive public health strategy based on the best available
data. At the same time, antismoking policies must be re-
spectful of human rights and avoid promoting intolerance of
socially unacceptable behaviors.
Dr Simonich is correct to warn that a ban on advertising
could sharply reduce the cost of doing business for cigarette
manufacturers. Since the cigarettemarket exhibits some price
elasticity, significant increases in taxes may be necessary to
maintain or increase the price of cigarettes.
We support a multidimensional public health approach to
cigarette smoking, including tax increases, health education,
smoking prevention, and cessation programs. We urge some
caution regarding the remaining two suggestions made by
Simonich\p=m-\government-imposedsmoking restrictions and a
ban on the introduction of new brands of cigarettes.
Government-imposed smoking restrictions can represent a
broad spectrum of policies with widely varying impacts on
public health. While we support the restrictions on smoking
in public areas that many states and municipalities have
enacted, more aggressive government-imposed smoking re¬
strictions could be perceived as punitive and unduly invasive.
Most data on secondhand smoke are based on studies involv¬
ing long-term exposure rather than casual transient exposure
to smoke.1 For this reason, any government ban on smoking
would require careful assessment of both its public health
benefits as well as its potential intrusiveness. Policies, such
as an ad ban, that focus attention and responsibility squarely
on the tobacco industry for the risks of their product may
have certain benefits over policies directed at individual
smokers.
The proposal to ban the introduction ofnew cigarette brands
is also problematic. While government could constitutionally
ban the manufacture of cigarettes, it has chosen not to do so. If
government continued to allow the manufacture of cigarettes
but prohibited the introduction of new brands, it probably
would be regarded as arbitrary and capricious. In order for such
a law to pass constitutional muster, advocates would have to
showwhy newbrands pose a serious and special danger to pub¬
lic health over and above currently existing brands.
It is true that the empirical data to support a ban on
cigarette advertising are equivocal. However, given the vast
complexity of designing studies that show a causal relation¬
ship between advertising and smoking, any evaluation of a
ban must rest on a careful assessment of many factors. The
profound harms of smoking, the history of unsuccessful reg¬
ulation of the industry, the unique characteristics of ciga¬
rettes in American life, and the minimum burdens on First
Amendment values lead us to reiterate our conclusion that a
ban on cigarette advertising would be an important part of a
comprehensive public health strategy.
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Nicotine Inhaler for Smoking Cessation
To the Editor.\p=m-\Ina recent article, T\l=o/\nnesenet al1 suggest
that a nicotine inhaler in smoking cessation could be imple-
mented in general practitioner offices with high success rates
and that it would be "acceptable" to patients. In addition, the
program is described as "low intervention." Results from
their study do not support such statements.
Their study involved volunteers whowere recruited through
newspaper advertisements and who were motivated to quit
smoking. Furthermore, subjects came to the clinic for a total
of eight visits within 1 year, with each visit lasting "from 30
to 60 minutes." Subjects saw videotapes on smoking cessa-
tion, had group instructions about the use of the nicotine
inhaler, had assessments with fiscal and biological parame-
ters, and received individual counseling. Such broad and ex-
pensive interventions are admirable, but in my practice as
well as that of most primary care physicians, I don't think
they would be classified as low-intervention efforts. More-
over, I am surprised that despite such efforts, the placebo
group had only a 5% successful smoking cessation rate at 1
year. In a prior study by T0nnesen et al,2 23% of participants
in a smoking cessation trial who were randomized to placebo
were abstinent at 1 year.
The claim that nicotine inhalers will be acceptable to pa¬
tients also seems premature given experiences with the use
of the nicotine patch, the cost ofwhich has been unacceptable
for many of my patients. Will the nicotine inhaler, when it
reaches the market (as I'm sure it will) cost as much or more
than the patch when used at a per-unit dose? Furthermore,
did the patients in the study receive their inhalers free of
charge? If both answers are yes, then I expect that the
inhaler will be less acceptable than envisioned, thus making
success rates less than reported. Effectiveness trials with
other nicotine replacement strategies have shown them to be
less successful than that reported in controlled research
reports.3
Finally, did patients truly use an average of 3.8 inhalers
per day, with each inhaler on average good for 300 puffs, as
reported? If true, then the average patient puffed 1.2 per
minute every hour for 16 hours a day. Again, I am not sure
my patients would find this acceptable.
Adam Goldstein, MD
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In Reply\p=m-\Ourenrollment in the nicotine inhaler study was al-
most supersonic: all 286 smokers were enrolled in 5 days in the
afternoon after working hours. Many subjects felt that the ses-
sions were unsatisfactcorydue to the hurry and lack of personal
contact. The subjects saw a 7-minute videotape at entry only.
This could also be arranged in a primary care setting.We believe
that the primary care physician could take advantage of his or
her knowledge of, and partnership with, the smoker, and so the
consultation time need not bemore than 5 to 10 minutes. The low
success rate in the placebo group in our study is a reflection of
the minimal psychological support provided, combined with a
relatively low degree of motivation to quit in moderately
nicotine-dependent subjects. In contrast,we have attained high-
er success rates when we used nicotine gum in combination with
group meetings.1
The inhaler was delivered free of charge, which might have
enhanced compliance with the device. As the cost of the
inhalermight influence optimal usage, reimbursement for the
cost of the inhaler as well for other nicotine products would
be desirable.
The subjects using the active nicotine inhaler attained a
nicotine substitution that was 24% to 43% of their smoking
levels. They used from one to 14 inhalers daily. It is not
possible to see when the nicotine inhaler is empty. However,
the subjects were told to replace the inhaler when they felt
it had no more effect. It is our impression that they used the
inhaler almost as often during the day as when smoking
cigarettes but had to puff harder and more often compared
with when using cigarettes. Using the inhaler does not seem
to be more difficult than using the nicotine gum.
Last, we should optimize the implementation of smoking
cessation in general practice since the efficacy of this treat¬
ment in its current state is as cost-effective as other pre¬
ventive measures.2 Lack of time is not a legitimate excuse for
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Persistent Ear Discomfort and Neck Pain
To the Editor.\p=m-\Weread with interest the excellent synopsis
of otorhinolaryngologic causes of persistent ear discomfort
and neck pain by Leliever.1 In our experience, in addition to
eustachian tube dysfunction, an often overlooked cause of the
symptoms described is activation ofmyofascial trigger points
in the clavicular division of the sternocleidomastoid muscle
(although some have questioned the basic concept2,3).
As characterized by Travell and Simons,4 when activated
sternocleidomastoid trigger points are present and produce
characteristic referred ear and neck pain on one side in the
pattern described in the question posed to LeLiever,1 such
points are usually found on the opposite side as well. This
would account for the bilateral distribution of the patient's
pain, as well as her increased pain on flexion of her neck.
Travell and Simons note that persons with such trigger points
also often experience referred frontal headaches and referred
autonomic phenomena, especially postural dizziness and equi-
librium disturbances.4
Though some dispute the validity of the method,5,6 we have
had considerable success demonstrating such activated trig¬
ger points with liquid crystal thermography, validated by
thorough physical palpation of the clavicular division(s) of the
involved sternocleidomastoid muscle(s) and by disappear¬
ance of referred ear pain after treatment of the trigger
point(s). Occasionally, chronic ear pain can result from acti¬
vation of trigger points in the upper part of the deep layer of
the ipsilateral masseter muscle; an activated trigger point in
the medial pterygoid muscle can also produce chronic ear pain
on the same side, but this is often accompanied by more jaw
pain than was described in the case presented to LeLiever.4
David E. Conwill, MD, MPH
B. H. Cook, MD, PhD
University of Mississippi Medical Center
Jackson
1. LeLiever WC. Eustachian tube dysfunction. JAMA. 1993;269:809.
2. Deyo PA. Back pain: the history and physical examination. JAMA. 1993;269:356.
3. Deyo PA. TENS for chronic low back pain. N Engl J Med. 1990;323:1425.
4. Travell JG, Simons DG. Myofascial Pain and Dysfunction: The Trigger Point
Manual. Baltimore, Md: Williams & Wilkins; 1983:202-235, 249-259.
5. Cotton P. AMA's Council on Scientific Affairs takes a fresh look at thermography.
JAMA. 1992;267:1885-1887.
6. Swerdlow B, Dieter JNI. An evaluation of the sensitivity and specificity of med-
ical thermography for the documentation of myofascial trigger points. Pain.
1992;48:205-213.
Suicide Attempts and the Nicotine Patch
To the Editor.\p=m-\Withinrecent months, four pharmaceutical
manufacturers have brought nicotine replacement patches
onto the US market for the treatment ofnicotine dependence.
The package inserts for these nicotine patches warn physi-
cians that the risks of nicotine replacement therapy in pa-
tients with known cardiovascular or peripheral vascular dis-
ease should be weighed carefully against the benefits of smok-
ing cessation. We write to report the case of a patient with
known coronary artery disease who attempted suicide by
means of nicotine overdose using nicotine patches.
Report of a Case.\p=m-\Ourpatient was a 44-year-old man
who presented in October 1992 with a single episode of
major depression and recurrent suicidal ideation. Diagnos-
tic evaluation resulted in additional diagnoses of patholog-
ical gambling, alcohol dependence syndrome, and nicotine
dependence. The patient had undergone coronary angio-
plasty in August 1992 for coronary artery disease. Two
weeks prior to his October hospital admission, he at-
tempted suicide by means of nicotine overdose. He placed
seven 21-mg nicotine patches on his chest and began
smoking cigarettes, two at a time. Prior to applying the
patches, he had flushed the patch enclosures down the
toilet. It was his intent to precipitate myocardial infarc¬
tion, and he had planned to hurriedly remove the patches
and similarly dispose of them once he developed chest
pain. He also brewed and consumed a pot of double-
strength coffee. Approximately 2 hours into this attempt,
having experienced no chest pain or other untoward symp¬
toms, he became anxious that he might actually succeed in
his suicide attempt and abruptly removed all the patches
and discontinued smoking.
Comment.—We contacted Marion Merrell Dow Ine (oral
communicationwith ElizabethMcManamy, RPH, Global Prod¬
uct Safety Specialist, February 1993), the producer of Nico-
derm, regarding other reports ofoverdose or attempted over¬
dose with Nicoderm. The pharmaceutical company had four
reports of overdose on record, one of which was intentional
